Testing zasocitinib in adults with active Crohn's disease
Tests zasocitinib in adults with active Crohn's disease, a long-term gut inflammation.
Plain-language title generated from the registry record
Registry title: A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
Key facts
- Where
- Oxford, United KingdomSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07403968, who can take part
Where in United Kingdom
- Oxford Experimental Medicine Clinical Research FacilityOxford, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT07403968
- Record updated
- 24 August 2026
- Original description
Crohn's disease (CD) is a serious, long-term condition that can cause swelling (inflammation) and painful ulcers anywhere in the gut. This study will investigate whether zasocitinib can improve CD biology at the cellular and molecular level in adults. The main aims of this study are to better understand zasocitinib's mechanism of action in CD and evaluate how safe this treatment is.Read full original descriptionShow less
An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib (TAK-279) in Participants With Active Crohn's Disease
Crohn's disease (CD) is a serious, long-term condition that can cause swelling (inflammation) and painful ulcers anywhere in the gut. This study will investigate whether zasocitinib can improve CD biology at the cellular and molecular level in adults. The main aims of this study are to better understand zasocitinib's mechanism of action in CD and evaluate how safe this treatment is.
The participants will be treated with zasocitinib for 3 months (12 weeks) and will need to undergo a test where a doctor uses a thin, flexible tube with a tiny camera to look inside the large bowel (colon) and the end of the small bowel (ileum); this test is called ileocolonoscopy.
During the study, participants will visit the study clinic several times.
Inclusion: Men and women aged 18 to 75 years can participate in the study; Must have been diagnosed with Crohn's disease (CD) at least 1 month (30 days) before study start; Must have received other treatments for CD earlier but no longer tolerate these treatments or the treatment no longer helps.
Exclusion: Cannot have complications of CD which may require surgery; Cannot have current abscesses or abscesses that have been treated within 6 weeks before study start; Cannot have had any surgery inside the belly (intraabdominal) within 3 months before study start; Cannot have another condition that causes swelling (inflammation) in the bowel; Cannot have had infections up to 2 months (8 weeks) before study start; Cannot have had a removal of parts of the bowel within half a year (6 months) before study start; Cannot have or had a J-pouch; Cannot have given blood or plasma within 1 month (30 days) before study start; Cannot tolerate having blood taken with a needle from a vein (venipuncture); Additional entry criteria will be discussed with the study doctor.